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ABSTRACT 
Despite considerable progress within the cell therapy industry, unmet bioprocessing and 
logistical challenges associated with the storage and distribution of cells between sites of 
manufacture and the clinic exist. We examined whether hypothermic (4°C–23°C) 
preservation of human adipose-derived stem cells could be improved through their 
encapsulation in 1.2% calcium alginate. Alginate encapsulation improved the recovery of 
viable cells after 72 hours of storage. Viable cell recovery was highly temperature dependent, 
with an optimum temperature of 15°C. At this temperature, alginate encapsulation preserved 
the ability for recovered cells to attach to tissue culture plastic on rewarming, further 
increasing its effect on total cell recovery. On attachment, the cells were phenotypically 
normal, displayed normal growth kinetics, and maintained their capacity for trilineage 
differentiation. The number of cells encapsulated (up to 2 ×106 cells per milliliter) did not 
affect viable cell recovery nor did storage of encapsulated cells in a xenofree, serum-free, 
current Good Manufacturing Practice-grade medium. We present a simple, low-cost system 
capable of enhancing the preservation of human adipose-derived stem cells stored at 
hypothermic temperatures, while maintaining their normal function. The storage of cells in 
this manner has great potential for extending the time windows for quality assurance and 
efficacy testing, distribution between the sites of manufacture and the clinic, and reducing the 
wastage associated with the limited shelf life of cells stored in their liquid state. 
 
  
	
INTRODUCTION 
The medical applications of cell-based therapies have expanded considerably in recent years 
with an ever-increasing number of clinical trials being registered globally, many of which are 
in phase III of development. These encompass treatments for a wide range of conditions 
including cardiovascular disease, neurodegenerative diseases, cancer, liver disease, diabetes, 
skeletal disorders and eye diseases [1-3]. Accompanying this growing intensity in cell-based 
clinical research is the emergence of a number of Food and Drug Administration (FDA)- and 
European Medicines Agency (EMA)- approved cell therapy products (CTPs) to the market 
[4-9].  
Hypothermic storage involves maintaining a living biologic in a suspended state at 
temperatures above 0°C but below the mammalian normothermic range of 32-37°C [10]. Due 
to the biological and technical issues associated with cryopreservation, including the required 
use of cryoprotective agents, such as dimethyl sulfoxide (DMSO), which can be costly to 
remove [11], and the risk of thawing with a hold time as little as two hours before a loss in 
cell viability occurs [12], the majority of approved CTPs adopt hypothermic storage. This 
means that they are manufactured ‘just-in-time’ in relatively small unit numbers rather than 
being stockpiled; keeping production costs low [13]. It does however mean that storage time 
is restricted before cells experience considerable loss in viability and function. This could not 
only affect the therapeutic potency of the CTP, but also introduce variability in the final 
product: an unfavorable situation for cGMP compliance. 
Methods that improve the hypothermic preservation of cell viability, function and 
therapeutic potency offer a number of benefits throughout the complex CTP supply chain: i) 
extending the period for quality, safety and efficacy testing; ii) allowing distribution from the 
donor or bank to sites of processing; and iii) delivery to the clinic with reduced wastage 
associated with inadequate scheduling between different sites [14-16]. 	
	
 Human adipose-derived stem cells (hASCs) have received much attention as a source 
of mesenchymal stem cells (MSCs) for cell therapy applications in recent years, with over 
130 clinical trials being registered between February 2007 and April 2015 [17]. Despite this 
growing interest, the effect of hypothermic storage on hASC viability and function has been 
limited. Here we examine encapsulation in alginate hydrogels as a method to support hASCs 
during hypothermic storage.  
Alginate is a natural polysaccharide derived from seaweed that polymerizes rapidly in 
the presence of cations to form a biocompatible hydrogel [18], and as such, has gained 
considerable interest as a biomaterial for cell therapy applications [18-21]. Alginate 
encapsulation has previously been investigated for its protective effect on the hypothermic 
storage of rat hepatocytes, recombinant baby hamster kidney cells, human bone marrow-
derived mesenchymal stem cells (MSCs), mouse embryonic stem cells (ESCs), and human 
limbal epithelial stem cells [22-25]. Its potential to heighten the preservation of cells during 
hypothermic storage has been postulated to be due to its contribution to membrane 
stabilization and subsequent protection against the osmotic shock and mechanical stress 
experienced during storage and recovery [23].    
Here we describe the encapsulation of hASCs in alginate hydrogels, and investigate 
the conditions necessary for cell survival and function over short-term periods in hypothermic 
storage. We demonstrate the effectiveness of alginate-encapsulation in preserving cell 
viability and reveal the importance of controlling storage temperature for maximal viable cell 
recovery. Using an optimal storage temperature, we demonstrate the effectiveness of alginate-
encapsulation to preserve the ability of hASCs to attach and regain metabolic activity upon 
return to normothermia, proposing that this should be taken into account upon defining viable 
cell recovery. We further demonstrate that hypothermic storage maintains the expression of 
key stem cell markers and does not affect the capacity for cells to proliferate and differentiate 
	
into osteo-, adipo-, and chondrogenic lineages. Finally, we explore scalability and adaptation 
to a serum-free, xeno-free storage system.  
Taken together, we present alginate-encapsulation as a low-cost, simple method to 
improve the hypothermic preservation of hASCs, which has considerable potential in 
extending the shelf life of hypothermically stored CTPs for distribution throughout the cell 
therapy supply chain.        
 
MATERIALS AND METHODS 
hASC culture 
hASCs obtained from the subcutaneous fat of three healthy donors (Invitrogen, UK), were 
used for all experiments. Cells were isolated from both male and female subjects (aged 45-63 
years) and purity was determined by the manufacturer as cells being ≥95% positive for CD29, 
CD44, CD73, CD90, CD105, and CD166 and ≤ 2% positive for CD14, CD31 and CD45 
surface antigen expression. Following recovery from cryostorage, cells were seeded at 800 
cells/cm2 and maintained in reduced-serum (RS) growth medium [MesenPRO™ RS medium 
containing 2mM GlutaMAX™ and 1% (v/v) antibiotic-antimycotic (all from Life 
Technologies, UK)] in a humidified incubator at 37°C and 5% CO2 with medium changes 
every 3-4 days until approximately 80% confluency was reached. Cells were harvested using 
TrypLE™ Express enzyme (Life Technologies, UK).	 
 
Encapsulation, storage and release of hASCs  
Harvested cells were incubated with 1 µM Calcein-AM (eBioscience, UK) for 15 minutes 
before counting viable (stained) cells using a Countess® II FL automated cell counter 
(Invitrogen, UK). A 0.25 mL suspension of 0.5–2x106 cells in growth medium was mixed 
with 0.25 mL 2.4% (w/v) sodium alginate (Sigma, UK) in PBS (Invitrogen, UK) before 
	
casting into calcium alginate discs using 102 mM calcium chloride as described previously 
[22]. Following a brief wash in PBS, gelled discs were transferred into 2 mL cryovials 
containing 1 mL growth medium, sealed, and placed in a polystyrene box before transferring 
to an actively-cooled incubator set to a specified temperature (11-23°C) or refrigerator (4°C). 
Control (non-encapsulated) cell suspensions (0.25 mL) were added directly to 2 mL cryovials 
containing 1 mL growth medium before storing in the same manner as encapsulated samples. 
Following 72 hours of storage (during which time the cells were left undisturbed), cells were 
allowed to equilibrate to room temperature before dissolving the calcium alginate hydrogel 
encapsulating them using 3 mL 100 mM trisodium citrate (Sigma, UK) for 5 minutes at room 
temperature, with control samples being treated in the same manner. The effect of trisodium 
citrate treatment on control samples was additionally compared against non-treated cells. 
Trisodium citrate was diluted using PBS before separating cells by centrifugation and 
dissociating them with TrypLE™ Express enzyme for 5 minutes (necessary due to 
aggregation of control samples). An equal volume of growth medium was added and cells 
were thoroughly re-suspended prior to counting. For serum-free conditions, storage was set 
up as above but growth medium was substituted for either StemPro® MSC SFM (SFM) or 
HypoThermosol-FRS (H-FRS). For 4°C experiments in H-FRS, cells were added directly to 
chilled H-FRS and were not allowed to equilibrate to room temperature before release as per 
the manufacturer’s instructions.  
 
Assessment of viable cell recovery 
The number of viable cells released from hypothermic storage was enumerated by incubating 
cells with 1 µM Calcein-AM for 15 minutes at 37°C before counting viable (stained) cells 
using a Countess® II FL automated cell counter (Invitrogen, UK).  
 
	
Assessment of apoptosis and cell death  
Cells recovered from hypothermic storage were assessed for apoptosis and cell death using an 
Annexin V-FITC Apoptosis Detection Kit (eBioscience, UK) according to the manufacturers 
instructions. Staining was analyzed using a Canto II flow cytometer (BD Biosciences, UK) 
and cells were classified as being viable (unstained), early-apoptotic (Annexin V-positive) or 
late-apoptotic/dead (Annexin V- and/or PI-positive).   
 
Functional assessment of hASCs before and after storage 
hASCs were examined for their capacity to re-attach, regain metabolic activity, proliferate 
and differentiate into osteo-, adipo-, and chondrogenic lineages. Stored samples were 
compared to non-stored control (NSC) samples; obtained from the same cultures harvested 
prior to storage that were plated, incubated, and assessed using the exact same methodology 
as detailed below. 
 
Assessment of attachment and metabolic activity 
Following release from storage, cells were plated at 20,000 cells/cm2 in 24-well plates and 
incubated for 24 hours at 37°C, 5% CO2 in a humidified incubator. Metabolic activity was 
then assessed using the alamar blue assay (as described in [26]). After incubation at 37°C for 
3 hours, fluorescence was read at an excitation wavelength of 530-560nm and emission 
wavelength of 590nm using a Fluoroskan Ascent™ FL plate reader (Thermo Scientific, UK). 
The same cultures were then assessed for attached cell number using the methylene blue-
based assay for proliferation (as described in [27]). Following elution of the methylene blue 
stain, absorption was read at 650nm using an Infinite F50 plate reader (Tecan, UK) and 
attached cell number was determined using a standard curve.  
 
	
Assessment of proliferative capacity 
Cells were plated at 5,000 cells/cm2 in 24-well plates and incubated for 3, 6, 9, 12 and 15 days 
at 37°C, 5% CO2 in a humidified incubator. Cell number was determined using the methylene 
blue-based assay for proliferation (as above). Absorption was read at 650nm using an Infinite 
F50 plate reader (Tecan, UK) and cell number was determined using a standard curve.  
  
Trilineage differentiation induction 
For osteo- and adipogenic differentiation, the previously stored cells were plated at 5,000 
cells/cm2 in 96-well plates in growth medium for 4 days at 37°C, 5% CO2 in a humidified 
incubator, changing medium after 2 days, before replacing growth medium with either 
osteogenic or adipogenic medium [StemPro® Osteogenesis or Adipogenesis Differentiation 
Kits containing 1% (v/v) antibiotic-antimycotic (all from Life Technologies, UK)] and 
maintaining for up to 31 days with media changes every 2-3 days. For chondrogenic 
differentiation, 5 µL of growth medium containing 80,000 cells was seeded into the center of 
96-well round-bottomed plate and incubated for 2 hours at 37°C. 200 µL chondrogenic 
medium [StemPro® Chondrogenesis Differentiation Kit containing 1% (v/v) antibiotic-
antimycotic (both from Life Technologies, UK)] was then added and cultures were 
maintained at 37°C, 5% CO2 in a humidified incubator for up to 35 days with media changes 
every 2-3 days. Non-induced controls for all cultures were maintained in growth medium for 
the same time period.    
 
Assessment of differentiation  
All differentiation cultures were fixed with 10% (v/v) formaldehyde for 1 hour at room 
temperature and washed 3 times with ddH2O prior to staining. Osteogenic differentiation was 
examined by staining mineralized matrices with 1 mg/mL Alizarin Red S (pH 5.5, 
	
Ammonium Hydroxide) as described in [28], whilst adipogenic differentiation was assessed 
by staining lipid droplets with 1.8mg/mL Oil Red O in isopropanol as described in [29], both 
at room temperature for 30 minutes with gentle agitation. Excess stain was removed with 4 
sequential washes with ddH2O before capturing images. Alizarin Red S stain was eluted with 
150µL 10% (v/v) acetic acid (as adapted from [28]) for 30 minutes at room temperature with 
gentle agitation before removing 100 µL aliquots and determining absorbance at 405nm. Oil 
Red O stain was washed for 5 minutes with 60% isopropanol before eluting with 150 µL 
isopropanol containing 4% IGEPAL CA-630 for 30 minutes at room temperature, removing 
100 µL aliquots and determining absorbance at 520nm. Alizarin Red S and Oil Red O 
staining were quantified using a standard curve of known concentrations and absorbance was 
read using an Infinite F50 plate reader (Tecan, UK). Chondrogenic differentiation was 
assessed by staining cartilage-associated glycosaminoglycans with 0.1 mg/mL Alcian Blue 
8GX in 6 parts ethanol to 2 parts acetic acid at room temperature overnight in the dark. Non-
specific staining was washed 4 times with 6 parts ethanol to 4 parts acetic acid before 
capturing images. All components for staining and elution were purchased from Sigma 
Aldrich, UK.  
 
Assessment of cell surface marker expression 
Following release from storage, the cells were resuspended in sterile PBS and were labeled by 
incubation with the fluorochrome conjugated primary antibodies for 25 minutes at room 
temperature in the dark. After the incubation, the samples were washed with sterile PBS and 
centrifuged at 1500 rpm for 5 minutes. The cells were then resuspended in 300 μL PBS and 
analyzed with a Canto II flow cytometer (BD Biosciences, UK). The antibody panel used was 
composed of antibodies against CD14 and CD45 as negative MSC markers, CD90 and CD73 
as positive MSC markers, CD29, CD44 and CD166 as adhesion markers present on the 
	
surface of MSC, as well as HLA-ABC and HLA-DR. Samples were run at a medium flow 
rate (60 μL/minute). Isotype controls were performed with antibodies against IgG1 and 
10,000 events, excluding cellular debris, were analyzed for each sample. All antibodies were 
obtained from BD Biosciences (UK) with the exception of the IgG1 isotype control 
(Beckman-Coulter, UK) and anti-CD90 (Dako, UK) antibodies. 
 
Statistical analyses 
Statistical analysis was carried out using GraphPad Prism (v4.00). Data are expressed as 
means of values from three separate donors ± standard error of the mean (SEM). Statistical 
comparisons were made using one-way or two-way repeated measures Analysis of Variance 
(ANOVA) with Bonferroni post hoc tests, with the exception of comparisons between two 
single variables where paired two-tailed T-tests were used. P-values < 0.05 were considered 
significant (*p < 0.05; **p < 0.01; ***p < 0.001). 
 
RESULTS 
The effect of storage temperature on viable cell recovery 
In order to elucidate the storage temperature that would achieve the greatest recovery of cells, 
we encapsulated hASCs in 1.2% alginate discs and stored them for 72 hours at various 
temperatures, comparing viable cell recovery to non-encapsulated controls. We found that 
hASCs were surprisingly sensitive to deviations in changes in storage temperature over 72 
hours. At 4°C, non-encapsulated (control) samples demonstrated a dramatic decrease in viable 
recovery, yielding only 17.8±15.6% of viable cells initially stored; a significantly lower 
recovery compared to any other temperature examined (Fig. 1A, 1B). Conversely, 
encapsulated cells exhibited a 3.7±0.7-fold increase in the number of viable cells recovered (P 
= 0.0224). Temperature had no significant effect on the viable cell recovery of control 
	
samples at any other temperature tested, but did increase from 11°C reaching an optimum 
storage temperature at 15°C (63±5% viable recovery) before demonstrating greater variability 
between 17 and 23°C, with an average viable recovery of approximately 50 percent (Fig. 1A, 
1B). Similarly, 15°C was the optimum temperature for storage of alginate-encapsulated cells, 
achieving a viable cell recovery of 86±6%, a significantly higher recovery compared to 
control samples (P = 0.0002) (Fig. 1A, 1B). At temperatures below or above 15°C, viable cell 
recovery did decrease slightly following storage in alginate, but only at 23°C was there a 
significant decrease in cell recovery compared to all other temperatures tested, with a 
heightened level of variability in the percentage viable recovery (29±29%) (Fig. 1A, 1B). Of 
note, the storage of encapsulated hASCs at 13-19°C consistently delivered a percentage viable 
recovery greater than 70 percent, the minimum acceptable viability specification generally set 
by the FDA for cellular products [30], and this was clearly not achieved without alginate 
encapsulation (Fig. 1A, 1B). As 15°C storage resulted in the greatest viable cell recovery in 
both control and encapsulated samples, subsequent experiments were conducted at this 
storage temperature.  
 
Assessment of apoptosis and cell death in stored-cell populations 
As well as determining viable cell recovery after 72 hours of hypothermic storage, we aimed 
to assess the contribution of apoptosis and death in recovered cell populations. Whilst non-
encapsulated (control) samples predominantly exhibited a viable population of cells (Fig. 2Ai, 
2B), this was variable (77±14.2%) with contribution of propidium iodide-stained dead cells, 
and propidium iodide and Annexin V co-stained late-apoptotic cells (11.3±7.2% and 
8.6±7.1% respectively). Neither control (Fig. 2Ai) nor encapsulated (Fig. 2Aii) samples 
exhibited a large population of Annexin V-stained early-apoptotic cells (2.7±0.4% and 
2.7±0.9% respectively). Encapsulated cells consistently exhibited a high level of viability 
	
(92±2.3%) confirming a healthy population of recovered cells with little contribution of 
apoptosis or death (Fig. 2Aii, XB). Thus, encapsulation both enhanced viability and reduced 
variability in the health of cell populations recovered from hypothermic storage.    
 
Attachment, metabolic activity and total viable recovery of stored cells 
In addition to examining the viability of cells following release from storage, it was also 
important to perform subsequent tests to ensure cells were functional. We therefore examined 
the ability for stored cells to re-attach to tissue culture plastic and recover metabolic activity 
24 hours after returning to a cell culture environment. Whilst non-encapsulated (control) 
hASCs exhibited a significant decrease in attached cell number compared to the non-stored 
control (NSC), encapsulated cells did not (Fig. 3A). A similar trend was observed with the 
percentage metabolic activity of cultures, although not significant (Fig. 3B). Furthermore, 
when normalized to cell number and expressed as the fold change relative to the NSC (Fig. 
3C), no change in metabolic activity per cell was evident. Utilizing this data, a value can be 
calculated that represents total percentage recovery, that is the percentage of viable cells able 
to attach and recover metabolic activity [total % recovery = % viable recovery × (fold change 
in attachment x fold change in metabolic activity/cell)]. Using this equation, the protective 
effect of encapsulation in preserving functional cell recovery is highlighted (Fig. 3D), whilst 
control conditions only yielded a 45±3% recovery, the alginate-encapsulated samples 
achieved a significantly higher 80±3% recovery (P = 0.0053). As trisodium citrate was 
required for the dissolution of alginate for cell release, and this variable was matched between 
control and encapsulated samples, it was also important to determine whether citrate itself 
could have influenced the outcome with regards to the control. We determined that trisodium 
citrate had no significant effect on cell recovery, attachment, metabolic activity or total 
percentage recovery compared to non-treated controls (supplement online Fig. 1A-D). 
	
Importantly, both yielded a total percentage recovery similar to the control presented here of 
42±1% and 43±4% in citrate-treated and non-treated samples respectively.    
 
Morphology and proliferative potential of hASCs following storage 
Following their subsequent attachment to tissue culture plastic, stored hASCs exhibited a 
normal spindle shaped fibroblast-like morphology, indistinguishable between any of the 
conditions, forming tightly packed confluent monolayers by twelve days in culture (Fig. 4A).  
The proliferative potential of hASCs was unaffected by storage and, although control samples 
exhibited a cell number lower than encapsulated samples at every time point, this was not 
significant (Fig. 4B). Growth kinetics were normal in all samples demonstrating a rapid 
exponential period of growth up to day 6 which plateaued after this point (Fig. 4C). 
 
Differentiation potential of cells following storage 
When induced to do so, hASCs have the capacity to differentiate into osteogenic, adipogenic 
and chondrogenic lineages. In order to investigate whether this differentiation potential was 
maintained following alginate encapsulation, hypothermic storage and release, hASCs were 
induced to differentiate to appropriate lineages for up to 35 days. All samples were able to 
differentiate into osteocytes, adipocytes and chondrocytes as demonstrated by Alizarin Red S, 
Oil Red O and Alcian Blue staining respectively (Fig. 4D). Although quantification of 
Alizarin Red S (Fig. 4Ei) and Oil Red O (Fig. 4Eii) staining suggested a slight conservation 
of differentiation capacity by alginate encapsulation, this was not significant.  
 
Immunophenotype of cells following storage 
In order to determine whether storage at 15°C for 72 hours affected the immunophenotype of 
encapsulated hASCs, flow cytometric analysis was performed and compared to non-stored 
	
cells maintained in culture at 37°C. In terms of size (FSC) and granularity (SSC), a similar 
profile was observed between cells obtained from culture (fig. 5A) and from storage (fig. 5B), 
with density plots indicating two distinct populations of different cell sizes. Non-stored 
hASCs exhibited a high level of expression of the MSC-associated markers CD73 and CD90 
(fig. 5C) that was maintained following storage, albeit at a slightly lower percentage (fig. 5D). 
Of the MSC-associated markers that have key roles in cell-cell interaction and cell adhesion, 
CD29 expression was high in both non-stored and stored cell populations, whilst the 
expression of CD44 and CD166 were considerably decreased following storage (fig. 5C&D). 
The expression of negative MSC markers CD14 and CD45 as well as HLA-DR and HLA-
ABC remained unchanged (fig. 5C&D).  
 
Effect of cell density on viable cell recovery 
For the purpose of scalability in the number of cells that could be preserved in calcium 
alginate, we investigated the viable recovery of cells after storage at up to 2 × 106 cells/mL, 
representing a four-fold increase in cell density. We found that encapsulation up to this 
density (1 × 106 cells in a 0.5 mL calcium alginate disc) did not compromise the recovery of 
cells, as the encapsulated samples consistently yielded an above 70 percent viable recovery 
whilst control samples resulted in a less than 70 percent viable recovery (Fig. 6). Alginate-
encapsulation at the highest cell concentration tested (2 x 106 cells/mL) significantly 
improved viable cell recovery compared to control  (P = 0.0484). 
 
Examination of storage in serum-free conditions 
For the purposes of adoption of a cell storage system into cell therapy logistics, it is important 
to demonstrate that any such system can be adapted to be serum-free, xeno-free and cGMP-
compliant. For this reason, we examined hypothermic storage in two commercially available 
	
serum-free, cGMP compliant medium: StemPro MSC SFM medium (SFM), formulated for 
MSC expansion, and HypoThermosol-FRS, a biopreservation medium designed for 
hypothermic storage at 4°C (H-FRS). These were compared against storage in the reduced-
serum growth medium (RSM). Whilst storage of cells at 15°C in SFM, did not significantly 
compromise viable cell recovery compared to RSM in either control or encapsulated 
conditions, storage in H-FRS resulted in a significant decrease in the number of viable cells 
recovered (Fig. 7A). As H-FRS is formulated for 4°C, we also examined storage at this 
temperature and again observed a lower viable cell recovery compared to 15°C. This 
surprising result confirmed the unsuitability of H-FRS for storage of hASCs in suspension. 
Conversely, storage in SFM resulted in a comparable total percentage recovery to RSM 
(73±12%) (Fig. 7B) and maintained the cytoprotection elicited by alginate-encapsulation (P = 
0.0188), confirming its suitability for hASC storage in serum-free, xeno-free conditions.   
 
DISCUSSION 
Despite extensive progress being made within the cell therapy industry, major logistical 
complications exist for cell storage and distribution. Here we present a simple, low-cost 
system capable of heightening the preservation of cells stored at hypothermic temperatures. 
Alginate-encapsulation has previously been demonstrated to be efficacious in the preservation 
of human bone marrow-derived MSCs, mouse ESCs, and human limbal epithelial stem cells 
at ambient temperature [22, 25], as well as rat hepatocytes and recombinant baby hamster 
kidney cells at 4°C [23, 24]. Here we explore this system further, elucidating the optimal 
storage conditions for cell survival and more fully characterizing cells upon release from 
storage.  
 The examination of hypothermic preservation of MSCs has previously been reported 
on cells derived from different tissues and at different storage temperatures including: (i) bone 
	
marrow at 4°C [31-38], 24°C [33, 35], ambient temperature [22, 36], and 37°C [35]; (ii) 
adipose tissue at 4°C [39, 40], 8°C, 25°C and 37°C [40]; and (iii) umbilical cord at 4°C [41]. 
Although these studies presented promising findings, the majority had been conducted at 4°C. 
Where direct comparisons between temperatures other than 4°C have been investigated, it has 
involved relatively large (greater than 12°C) steps in temperatures studied. Here we have 
demonstrated that small changes in temperature can have a considerable effect on the viable 
recovery of alginate-encapsulated cells with an optimal temperature in the range of 13-19°C 
and the greatest level of recovery at 15°C in both non-encapsulated and encapsulated samples. 
The importance of temperature on enzyme activity and subsequent metabolic rate of cells is 
likely to be key to this observation where there is an optimal point in which cell metabolism is 
slowed sufficiently for relative quiescence, before lower temperatures induce a phase 
transition in the cell membrane resulting in the segregation of membrane proteins and the 
uncontrolled entry of ions and subsequent cellular edema [42]. Previously, when protein 
leakage from liposomes was examined during chilling at a rate of 0.5°C/min, leakage was 
initiated below 15°C [43], which could go some way to explain why viable cell recovery 
decreases at temperatures lower than this in our system. Interestingly though, alginate-
encapsulation elicited its highest level of cytoprotection at 4°C but did not result in a recovery 
better than that shown at 13-19°C.  
At temperatures as high as 23°C, viable cell recovery decreases considerably, likely 
due to the temperature being too high to suppress enzyme activity and subsequent metabolism 
of cells. The result of this being the activation of dormant cells with ensuing metabolic 
requirements, and a further sensing of the sub-optimal environment for survival. What is 
more, the combination of higher hypothermic temperatures and alginate encapsulation 
appears to worsen viable recovery. Alginate is an inert hydrogel in which cells are suspended 
	
and separated from each other resulting in little or no physical cell-cell interaction that may 
offer protection at higher temperatures. Whilst the effect of higher temperatures being 
detrimental for hypothermic preservation is perhaps unsurprising, it is pertinent that this 
occurs at what might be considered as a low ambient temperature of 23°C. This emphasizes 
the importance of controlling temperature during storage. We have, however, demonstrated 
that there is a range of suitable temperatures (13-19°C) where viable recovery was 
consistently above 70% suggesting a degree of tolerance to possible deviations during storage 
and distribution. This optimal temperature range for hypothermic preservation is consistent 
with studies on adherent retinal pigment epithelial cells [44] and cultured conjunctival 
epithelium [45], as well as Chinese hamster ovary (CHO) cells stored in suspension [46]. 
These studies similarly demonstrated that the storage of cells at 4°C or the upper range of 
hypothermic temperatures, was highly detrimental for cell survival. The application of non-
chilled (above 4°C) hypothermic temperatures for CTP preservation is also reflective of the 
storage conditions employed by approved CTPs including ChondroCelect® (15-22°C), 
Epicel® (13-23°C) and Apligraf® (20-23°C) [4, 6, 8]. Taken together, controlled, non-chilled 
conditions are optimal for cell preservation in this system. 
 With CTP consistency and lack of variability being an important concern for cell 
delivery, we examined the contribution of early-apoptotic, late-apoptotic and dead cells in 
populations released from storage at 15°C. As well as the increased viable cell recovery 
effected by encapsulation, it also resulted in a consistently high viability in the cell population 
recovered with little incidence of apoptosis or death. This, on the other hand, was highly 
variable in non-encapsulated cell populations. With the major cause of cell death during 
hypothermic preservation being a result of membrane destabilization, ultimately resulting in 
cellular edema and lysis [42], we were not able to account for all cells present prior to storage, 
likely due to the nature of cell death resulting in full membrane disintegration. Due to this 
	
common effect of cell preservation, the presentation of percentage viability as a measure of 
storage success can often be anomalous. These results support the fact that the encapsulation 
of hASCs is able to yield a consistently high recovery of viable cells, compared to those 
present prior to storage, and the end product has minimal contribution of death and/or 
apoptosis. 
 Whilst it is of great importance to examine viable cell recovery as a quality control 
measure for CTPs, it is also critical to assess cellular function after a period of rewarming. 
Such assessment is important due to the possibility of the activation of stress-pathways up to 
24 hours post-return to normothermia as previously described following cryopreservation 
[47], as well as in the reported effects of attenuated attachment of bone marrow-derived 
MSCs following hypothermic storage [38]. Herein we have demonstrated that encapsulation 
protected against the decrease in attached cell number exhibited by non-encapsulated samples 
after 24 hours in culture, with no change in metabolic activity per cell. We believe it 
important to take these measurements into account when calculating a value for ‘total 
percentage viability’, i.e. the number of viable cells released from storage that are able to 
attach and recover normal metabolic activity. Through using this approach (multiplying the 
viable cell recovery by the fold change in attachment multiplied by the metabolic activity per 
cell) for every donor, we can take into account all permutations that represent a final recovery 
of cells upon return to tissue culture. Consequently, any deviations in attachment or metabolic 
activity are represented. There is also a degree of normalization with those samples that 
achieving the highest level of viable recovery, also having the lowest level of attachment. 
This suggests that a population of cells that are counted as viable may already be damaged but 
this only becomes apparent when cells are rewarmed on return to normal tissue culture 
conditions. Thus we can exclude those cells that would not survive upon return to 
	
physiological conditions producing a reliable, consistent measure of recovery. This approach 
has also highlighted the increased functional cell yield effected by alginate.  
Upon cell reattachment, morphology was shown to be unaffected compared to non-
stored controls moreover the released cells exhibited a normal pattern of growth, an important 
concern considering the previous reports of attenuated growth of bone marrow-derived MSCs 
following hypothermic storage [34]. As well as attachment and growth characteristics, one of 
the most important functional characteristics of MSCs is their ability to differentiate into 
osteoblasts/osteocytes, adipocytes and chondroblasts/chondrocytes [48], a capacity reported to 
be diminished after short-term hypothermic storage [36]. However, under the conditions 
tested here, we observed no difference in the capacity for trilineage differentiation following 
storage when compared to non-stored controls. Although encapsulation did appear to elicit 
greater protection against reduced proliferation and differentiation compared to non-
encapsulated controls, this was only slight and not significant after 72 hours storage.  Thus, 
alginate-encapsulation elicited a 1.79±0.15-fold increase in the total percentage recovery of 
hASCs that maintained a normal phenotype and function following release from storage at 
15°C for 72 hours.  
In support of hypothermic storage in alginate being able to hold cells in an un-altered 
state, we demonstrated that a high expression of the majority of MSC-associated markers was 
maintained following storage, importantly CD90 and CD73, albeit at a lower level. We did, 
however, observe a considerable decrease in the expression of two MSC-markers associated 
with adhesion (CD44 and CD166). This is perhaps unsurprising as alginate is an inert 
polymer and, as such, the interaction of encapsulated-cells with their surrounding 
environment would be minimal, which may have resulted in their expression being lost. 
Indeed, it has previously been reported that the expression of a number of cell surface 
markers, including CD44, CD90 and CD166, are diminished during the culture of human 
	
bone marrow-derived MSCs in alginate, but these are recoverable following return to 
monolayer culture [49]. Thus, certain MSC-associated markers may not be appropriate for 
assessing cells released directly from alginate.  
With the clinical application of MSCs requiring high cell numbers, typically 1-2 × 106 
cells/kg depending on the treatment [50], it was necessary to examine whether viable cell 
recovery was compromised at higher cell densities. The cytoprotection offered by alginate 
encapsulation was maintained, in cell densities of up to 2 × 106 cells/mL, resulting in a viable 
cell recovery consistently above 70 percent. This suggests that scaling up to higher cell 
numbers is feasible and, accompanied by scalable platforms for cell encapsulation in alginate 
beads [51], makes scalable process development of large numbers of therapeutic cells 
achievable.  
As fetal bovine serum (FBS) could be a source of prion, viral and zoonotic diseases 
[52], it was also desirable to examine whether the cytoprotection offered by alginate 
encapsulation could be recapitulated when hydrogels were placed in serum-free, xeno-free 
and cGMP-grade storage medium. Whilst HypoThermosol-FRS has demonstrable efficacy in 
the preservation of adherent bone marrow-derived MSCs at 4°C [32, 37] and offers 
cytoprotection to hypothermically stored hepatocytes in suspension [53], we found it 
unsuitable for storage of hASCs in suspension at either 4°C or 15°C. Conversely 
commercially available StemPro® MSC SFM medium affected no significant difference in 
viable cell recovery or total percentage recovery of cells when compared to MesenPro 
reduced serum (RS) medium. This demonstrated that the storage system, described here, 
could be easily adapted to be clinically safe and cGMP-compliant. 
Although we have provided convincing evidence that alginate-encapsulation improves 
the hypothermic preservation of hASCs, the mechanism by which it exerts its effect remains 
unclear. It has been suggested, during the hypothermic preservation of hepatocytes, that 
	
alginate encapsulation functions to stabilize the membrane of suspended cells in the absence 
of an extracellular matrix, and thus minimize the effects of osmotic shock and mechanical 
stress during cell storage and recovery [23]. Alginate also has a strong influence on ion and 
solute diffusion throughout the hydrogel matrix [54], as well as having a considerable 
swelling capacity. This could contribute to modulating the diffusion rates of ions and solutes, 
and therefore water [42], in the environment surrounding encapsulated cells, further reducing 
the impact of osmotic shock and cellular edema. Thus, there are a number of mechanisms by 
which alginate could offer cytoprotection during hypothermic storage.  
 
CONCLUSION 
In a recent assessment by experts in the field, it was considered that the development of 
preservation and transport-enabling technologies were critical in the cell therapy industry in 
order to eliminate GMP-regulated steps of preservation removal and cell thawing associated 
with cryopreservation [14]. Although liquid-state storage avoids these issues, there still 
remains concern over limited time-windows associated with the transfer of cells to the clinic 
due to a restricted shelf life where high levels of material wastage can result [55]. Alginate-
encapsulation represents a method whereby the hypothermic preservation of cells can be 
markedly improved whilst maintaining cell functionality. As a material with demonstrable 
biocompatibility, application in cell therapy, and scalability, its integration into CTP 
bioprocessing has considerable potential.      
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FIGURES 
 
 
Figure 1. The effect of storage temperature on viable cell recovery. hASCs were stored at 
different temperatures either encapsulated (Encaps.) or non-encapsulated (Control) for 72 
hours before assessing viable cell number (A) and percentage viable recovery (B). Values are 
expressed as means ± SEM from 3 separate donors with asterisks representing significance 
from control values (***p < 0.001; *p < 0.05) and symbols representing significance between 
temperatures ($$ or ##: p > 0.05; $#: p < 0.05).  
  
	 
Figure 2. Assessment of apoptosis and cell death in stored cell populations. hASCs were 
stored at 15°C for 72 hours before assessing the percentage of cells positive for Annexin V, 
and/or propidium iodide in non-encapsulated control (Ai) and encapsulated (Aii) cell 
populations. Cells were classified as being viable (unstained), early-apoptotic (Annexin V-
positive) or late-apoptotic/dead (Annexin V- and/or PI-positive) cells (B). Values are 
expressed as means ± SEM from 3 separate donors.  
  
	 
Figure 3. Attachment, metabolic activity and total cell recovery following storage. hASCs 
were stored at 15°C for 72 hours before returning a cell culture environment. After 24 hours, 
cell attachment (A) and metabolic activity (B, C) were assessed. These values were used to 
calculate total percentage recovery [% viable recovery × (fold change in attachment x fold 
change in metabolic activity/cell)] (D). Values are expressed as means ± SEM from 3 separate 
donors with asterisks representing significance from control values (**p < 0.01; *p < 0.05). 
NSC: non-stored control; Control: non-encapsulated; Encaps.: encapsulated. 
  
	 
Figure 4. Morphology, proliferation and multilineage differentiation potential following 
storage. hASCs were stored at 15°C for 72 hours before returning a cell culture environment. 
Cells were cultured in growth medium with images being captured after one and twelve days, 
(A) and cell number was assessed every three days for fifteen days (B, C). For differentiation, 
cells were cultured in osteo-, adipo-, or chondrogenic media for up to 35 days. Cultures were 
stained with Alizarin Red S (osteogenic), Oil Red O (adipogenic) or Alcian Blue 8GX 
(chondrogenic) and images were captured (D). Osteogenic (Ei) and adipogenic (Eii) stains 
were quantified. A: scale bars = 100µm; B, C, E: values are expressed as means ± SEM from 
three separate donors; D: scale bars = 50µm. NSC: non-stored control; Control: non-
encapsulated; Encaps.: encapsulated.  
	 
Figure 5. Assessment of size, granularity and immunophenotype of encapsulated cells 
following storage. hASCs were assessed for size and granularity following no storage (A) and 
storage for 72 hours at 15°C (B). Similarly, immunophenotype was assessed following no 
storage (C) and storage for 72 hours at 15°C (D). Size and granularity plots denote 
representative images and values for the percentage expression of cell surface markers are 
expressed mean ± SEM from three separate donors.  
  
	 
Figure 6. The effect of cell load on viable cell recovery following storage.  hASCs were 
stored at 15°C for 72 hours at a range of densities before assessing viable cell recovery. 
Values are expressed as means ± SEM with the level for 70% viable cell recovery indicated 
by a dotted line. Control: non-encapsulated (R2 = 0.9268); Encaps.: encapsulated (R2 = 
0.9859). 
  
	 
Figure 7. Cell storage in serum-free, xeno-free, cGMP-grade medium. hASCs were stored at 
15°C for 72 hours in growth medium (reduced-serum medium [RSM]) or serum free medium 
[SFM] or at 15°C or 4°C in HypoThermosol-FRS (H-FRS) before assessing viable cell 
recovery (A). Total % Recovery (B) was calculated with attachment and metabolic activity 
data using the following equation [% viable recovery × (fold change in attachment x fold 
change in metabolic activity/cell)]. Values are expressed as means ± SEM from 3 separate 
donors with asterisks representing significance from control values (***p < 0.001; **p < 
0.01; *p < 0.05) and symbols representing significance between storage media ($$ or ##: p > 
0.05; $#: p < 0.05). Control: non-encapsulated; Encaps.: encapsulated. 
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Figure 1. The impact of sodium citrate on the viable cell recovery, attachment, metabolic activity and 
total cell recovery of non-encapsulated cells following storage. hASCs were stored at 15°C for 72 
hours before assessing viable cell number (A) and returning a cell culture environment. After 24 hours, 
cell attachment (B) and metabolic activity (C) were assessed. These values were used to calculate 
total percentage recovery [% viable recovery × (fold change in attachment x fold change in metabolic 
activity/cell)] (D). Values are expressed as means ± SEM from 3 separate donors with asterisks 
representing significance from control values (**p < 0.01; *p < 0.05). NSC: non-stored control. 
 
 
